Picture of Cassava Sciences logo

SAVA Cassava Sciences Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

Momentum

Relative Strength (%)
1m+16.9%
3m+38.72%
6m+20.89%
1yr+13.03%
Volume Change (%)
10d/3m-50.44%
Price vs... (%)
52w High-33.36%
50d MA+26.41%
200d MA+26.54%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-69.85%
Return on Equity-8.35%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Cassava Sciences EPS forecast chart

Profile Summary

Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on neuroscience. The Company's science is based on stabilizing, but not removing, a critical protein in the Alzheimer’s brain. Its scientific approach for the treatment of Alzheimer's disease seeks to simultaneously suppress both neurodegeneration and neuroinflammation. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease dementia. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer’s brain. It is conducting two randomized placebo-controlled Phase III clinical trials of oral simufilam in patients with Alzheimer’s disease dementia. SavaDx, its lead investigational diagnostic product candidate, is a way to detect the presence of Alzheimer’s disease from a small sample of blood. SavaDx is a research-use only, non-safety related exploratory biomarker.

Directors

Last Annual
December 31st, 2023
Last Interim
June 30th, 2024
Incorporated
May 4th, 1998
Public Since
July 14th, 2000
No. of Shareholders
28
No. of Employees
29
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
47,976,166

SAVA Share Price Performance

Upcoming Events for SAVA

Q3 2024 Cassava Sciences Inc Earnings Release

Q4 2024 Cassava Sciences Inc Earnings Release

Similar to SAVA

Picture of 180 Life Sciences logo

180 Life Sciences

us flag iconNASDAQ Capital Market

Picture of Abeona Therapeutics logo

Abeona Therapeutics

us flag iconNASDAQ Capital Market

Picture of ABVC Biopharma logo

ABVC Biopharma

us flag iconNASDAQ Capital Market

Picture of Acesis Holdings logo

Acesis Holdings

us flag iconNASDAQ Capital Market

Picture of Achieve Life Sciences logo

Achieve Life Sciences

us flag iconNASDAQ Capital Market

FAQ